Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry
Androgen receptor signaling inhibitors and docetaxel were the most common first- and second-line castration-resistant PC treatments. Enzalutamide was the preferred androgen receptor signaling inhibitor with the longest treatment duration.
Authors
- Mizuki Onozawa (ORCID: https://orcid.org/0000-0001-9700-0274)
- Taketo Kawai (ORCID: https://orcid.org/0000-0002-7279-2874)
- Satoshi Uno (ORCID: https://orcid.org/0000-0002-8209-6864)
- Takeshi Mitomi
- Atsushi Saito (ORCID: https://orcid.org/0000-0003-2425-3371)
- Haruki Kume
- Shiro Hinotsu (ORCID: https://orcid.org/0009-0001-3111-695X)
Institutions
- Sapporo Medical University (JP)
- Astellas Pharma (Japan) (JP)
- Data Management (Italy) (IT)
- The University of Tokyo (JP)
- International University of Health and Welfare (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-04-13
- DOI
- https://doi.org/10.1093/jjco/hyaf061
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Pfizer
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders